(Press-News.org) Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology (ASH) Meeting & Exposition, occurring in San Diego, California and virtually December 9-12, 2023. The presentations focus on treatments for acute leukemias and lymphomas.
Among the data are the promising results of the phase 2 PrE0405 trial, which evaluated bendamustine, rituximab, and venetoclax for the initial treatment of mantle cell lymphoma in older patients. Other abstracts are secondary analyses from the practice-changing E1910 phase 3 trial (Abstract LBA-1 at ASH 2022). Details for the nine presentations are below, listed by type and date.
Oral Presentations
The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia
Presenter: Satoshi Yoshimura, MD (St. Jude Children's Research Hospital)
Date and Time: Sunday, December 10, 4:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 596 in Session 618 (entire session 4:30-6:00 PM)
Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN E2906 Phase 3 Trial
Presenter: James M. Foran, MD (Mayo Clinic Florida)
Date and Time: Sunday, December 10, 5:45 PM
Location: Pacific Ballroom Salons 24-26, Marriott Marquis San Diego Marina
Abstract 594 in Session 613 (entire session 4:30-6:00 PM)
Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)
Presenter: Craig A. Portell, MD (University of Virginia Medical Center)
Date and Time: Monday, December 11, 10:30 AM
Location: Grand Hall B, Manchester Grand Hyatt San Diego
Abstract 733 in Session 623 (entire session 10:30 AM-12:00 PM)
Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome
Presenter: Ilaria Iacobucci, PhD (St. Jude Children's Research Hospital)
Date and Time: Monday, December 11, 2:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 841 in Session 618 (entire session 2:45-4:15 PM)
STAG2/LMO2 Gamma-Delta (γÎ') T-Cell Acute Lymphoblastic Leukemia: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
Presenter: Shunsuke Kimura, MD, PhD (St. Jude Children's Research Hospital)
Date and Time: Monday, December 11, 3:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 845 in Session 618 (entire session 2:45-4:15 PM)
Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
Presenter: Catherine S. Diefenbach, MD (Perlmutter Cancer Center at NYU Langone Health)
Date and Time: Sunday, December 10, 4:30 PM
Location: Grand Hall B, Manchester Grand Hyatt San Diego
Abstract 607 in Session 624 (entire session 4:30-6:00 PM)
Poster Presentations
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
Presenter: Selina M. Luger, MD, FRCPC (University of Pennsylvania)
Date and Time: Sunday, December 10, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 2877 in Session 614
AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Presenter: Tara O. Henderson, MD (University of Chicago Medical Center)
Date and Time: Sunday, December 10, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 3084 in Session 624
ECOG-ACRIN participated in this trial through a collaboration across the National Cancer Institute's National Clinical Trials Network (NCTN).
A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged Acute Myeloid Leukemia Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999
Presenter: Yaseswini Neelamraju (University of Virginia)
Date and Time: Monday, December 11, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 4326 in Session 617
Presenters are available for media interviews under the ASH news embargo policy.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1300 member institutions and 15,000 research professionals in the United States and around the world. It is funded primarily by the National Cancer Institute, part of the National Institutes of Health. Visit ecog-acrin.org, and follow us on Twitter @eaonc, Facebook, and LinkedIn.
About PrECOG
The PrECOG, LLC cancer research organization designs and conducts innovative oncology studies through industry partnerships and research networks. Its current portfolio includes phase 1 and 2 multi-center trials and US-based and multi-national phase 3 trials. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of the ECOG-ACRIN Cancer Research Group. Visit www.precogllc.org and follow us on Twitter @PrECOGonc, Facebook, and LinkedIn.
END
ECOG-ACRIN and PrECOG announce multiple presentations at the American Society of Hematology (ASH) 2023 annual meeting
2023-11-15
ELSE PRESS RELEASES FROM THIS DATE:
Use it or lose it: New robotic system assesses mobility after stroke
2023-11-15
Embargoed: Not for Release Until 2:00 pm U.S. Eastern Time Wednesday, 15 November 2023
Stroke is a leading cause of long-term disability worldwide. Each year more than 15 million people worldwide have strokes, and three-quarters of stroke survivors will experience impairment, weakness and paralysis in their arms and hands.
Many stroke survivors rely on their stronger arm to complete daily tasks, from carrying groceries to combing their hair, even when the weaker arm has the potential to improve. Breaking this habit, known as “arm nonuse” or “learned nonuse,” can improve strength and prevent injury.
But, determining how much ...
Birds set foot near South Pole in Early Cretaceous, Australian tracks show
2023-11-15
The discovery of 27 avian footprints on the southern Australia coast — dating back to the Early Cretaceous when Australia was still connected to Antarctica — opens another window onto early avian evolution and possible migratory behavior.
PLOS ONE published the discovery of some of the oldest, positively identified bird tracks in the Southern Hemisphere, dated to between 120 million and 128 million years ago.
“Most of the bird tracks and body fossils dating as far back as the Early Cretaceous are from the Northern Hemisphere, particularly from Asia,” says Anthony Martin, first ...
University of Kentucky bioengineer designs tools to improve treatment for head and neck cancer
2023-11-15
LEXINGTON, Ky. (Nov. 15, 2023) — One University of Kentucky researcher is working to develop new techniques for radiation treatment to improve survival rates of patients with a specific type of cancer.
Caigang Zhu, Ph.D., is an assistant professor in the Department of Biomedical Engineering in the UK Stanley and Karen Pigman College of Engineering. He is also a member of the Molecular and Cellular Oncology Research Program at the UK Markey Cancer Center.
The National Institute of Dental and Craniofacial Research of ...
New plant hardiness map, used by gardeners nationwide and based on OSU climate data, unveiled
2023-11-15
CORVALLIS, Ore. – The U.S. Department of Agriculture today released its new Plant Hardiness Zone Map, the national standard by which gardeners can determine which plants are most likely to survive the coldest winter temperatures at a certain location.
The USDA describes the latest map, jointly developed by Oregon State University’s PRISM Climate Group and the USDA’s Agricultural Research Service, as the most accurate and detailed it has ever released.
PRISM, part of the OSU College of Engineering, stands for Parameter-elevation Regressions on Independent Slopes Model. The previous version of the plant hardiness map, also based ...
An engineered protein enhances memory
2023-11-15
Neuroscientists at the Faculty of Medicine and Surgery of the Catholic University, Rome, and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS have genetically modified a molecule, the protein LIMK1, which is normally active in the brain, with a key role in memory. They added a "molecular switch" that is activated by administering a drug, rapamycin, known for its several anti-aging effects on the brain.
This is the result of a study published in the journal Science Advances, which involves the Catholic ...
New near-complete skeleton of a bird-like dinosaur is found in a position which suggests it slept like modern birds
2023-11-15
New near-complete skeleton of a bird-like dinosaur is found in a position which suggests it slept like modern birds
###
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293801
Article Title: A new alvarezsaurid dinosaur (Theropoda, Alvarezsauria) from the Upper Cretaceous Baruungoyot Formation of Mongolia provides insights for bird-like sleeping behavior in non-avian dinosaurs
Author Countries: Japan, Mongolia
Funding: Funding for this project was granted by Research Fellowships from the Japan Society for the Promotion of Science (JSPS 21J12938) (to KK) and Ami Koshimizu (Endless Glory Office Restart Co., Ltd.) (to KK). The funders had ...
Radiocarbon dating meets Egyptology and Biblical accounts in the city of Gezer
2023-11-15
New dates provide detailed insights into the timing of events in the ancient city of Gezer, according to a study published November 15, 2023 in the open-access journal PLOS ONE by Lyndelle Webster of the Austrian Academy of Sciences and colleagues.
Gezer is an ancient southern Levantine city, well known from Egyptian, Assyrian, and Biblical texts and associated with stories of power struggles and significant historical figures. It is also a rich archaeological site with abundant Bronze Age and Iron Age remains and with great potential for research into the daily lives of its denizens. Recent excavations at the site have uncovered a continuous stratigraphic ...
Women with breast cancer take sexual health into their own hands
2023-11-15
A third of users on a popular breast cancer support forum describe using peer-recommended or self-discovered techniques to improve sexual functioning, according to a study published November 15, 2023 in the open-access journal PLOS ONE by Christiana von Hippel from the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, USA, and colleagues.
Over 75 percent of breast cancer survivors describe experiencing some degree of sexual dysfunction. Commonly prescribed interventions such as vaginal lubricants or numbing creams are only moderately ...
Australian footprints are the oldest known evidence of birds from southern regions
2023-11-15
Early birds had made it to southern polar environments by 120 million years ago, according to a study published November 15, 2023 in the open-access journal PLOS ONE by Anthony Martin of Emory University, USA and colleagues.
Cretaceous bird fossils are abundant and diverse in northern continents, but extremely rare in southern continents, regions that were once part of the landmass of Gondwana. This presents a challenge for paleontologists trying to understand the distribution of early birds. In this study, Martin and colleagues report ...
Treatment strategy for certain advanced prostate cancers shows promise in preclinical models
2023-11-15
Study Title: Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
Publication: Science Translational Medicine [10.1126/scitranslmed.adf6732]
Dana-Farber Cancer Institute author: Himisha Beltran, MD
Summary: Epigenetic changes can cause prostate cancer to resist treatment by switching genes on or off. One epigenetic mechanism tags genes with DNA methylation marks. This process is mediated by molecules called DNA methyltransferases. These tags can alter gene expression in ways that promote tumors to grow and transition ...